Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Aripiprazole, brexpiprazole, and cariprazine: Not all the same: Understanding the key differences among these agents can help inform treatment decisions - Document - Gale Academic OneFile

Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Brexpiprazole: A New Treatment Option for Schizophrenia and Major Depressive Disorder - Marija Markovic, Alyssa Gallipani, Krina H. Patel, Megan Maroney, 2017

The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors, Biology Direct

Brain Sciences, Free Full-Text

Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies - ScienceDirect

Rexulti6001PPS0.JPG

Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena

Brexpiprazole - Wikipedia

hplc+uv

Brexpiprazole Semantic Scholar

Spotlight on brexpiprazole and its potential in the treatment of schiz